A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Lilly disclosed the initial weight loss results last December. Novo noted that Wegovy is approved to help prevent strokes and heart attacks, saying in a statement that “obesity is about more ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), compared with 5.1 in (13 cm) with Wegovy. The "head-to-head results demonstrated tirzepatide [Zepbound] led to ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.